Epitope mapping of neutralizing TSST-1 specific antibodies induced by immunization with toxin or toxoids

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3675-3684

  Gampfer, Jörg M ^a   Samstag, Aysen ^b   Waclavicek, Martina ^a   Wolf, Hermann M ^b   Eibl, Martha M ^a,b   Gulle, Heinz ^a  

^a Biomedizinische Forschungsgesellschaft mbH   (Austria)

^b Immunologische Tagesklinik   (Austria)

Author keywords

Epitope mapping; Immunization; Superantigen

Indexed keywords

ANTIBODY; ANTIGEN; FORMALDEHYDE; T LYMPHOCYTE RECEPTOR; TOXIC SHOCK SYNDROME TOXIN 1; TOXOID; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; ENTEROTOXIN; ENTEROTOXIN F, STAPHYLOCOCCAL; POLYETHYLENE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; STAPHYLOCOCCUS VACCINE; SUPERANTIGEN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; IMMUNE SYSTEM; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR BINDING; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE; TOXIC SHOCK SYNDROME; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; POLYETHYLENE; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECOMBINANT PROTEINS; STAPHYLOCOCCAL VACCINES; SUPERANTIGENS; TOXOIDS; VACCINES, SYNTHETIC;

EID: 0036841928     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00400-0     Document Type: Article

References (41)

1. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives [published erratum appears in Science 1990 Jun 1248(4959):1066] [see comments]. Science 1990 248(4956):705-711.
2. Schrezenmeier H. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J. Exp. Med. 167(5):1988;1697-1707.
3. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin. Microbiol. Rev. 8(3):1995;411-426.
4. Bergdoll M.S., Crass B.A., Reiser R.F., Robbins R.N., Davis J.P. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet. 1(8228):1981;1017-1021.
5. Bergdoll M.S., Reiser R.F., Crass B.A., Robbins R.N., Thompson N.E. Toxic shock syndrome - the role of the toxin. Postgrad. Med. J. 61(1):1985;35-38.
6. Bohach G.A., Fast D.J., Nelson R.D., Schlievert P.M. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit. Rev. Microbiol. 17(4):1990;251-272.
7. Schlievert P.M., Shands K.N., Dan B.B., Schmid G.P., Nishimura R.D. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J. Infect. Dis. 143(4):1981;509-516.
8. Schlievert P.M. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet. 1(8490):1986;1149-1150.
9. Blomster-Hautamaa D.A., Kreiswirth B.N., Novick R.P., Schlievert P.M. Resolution of highly purified toxic-shock syndrome toxin 1 into two distinct proteins by isoelectric focusing. Biochemistry. 25(1):1986;54-59.
10. Acharya K.R., Passalacqua E.F., Jones E.Y., Harlos K., Stuart D.I., Brehm R.D.et al. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature. 367(6458):1994;94-97.
11. Prasad G.S., Earhart C.A., Murray D.L., Novick R.P., Schlievert P.M., Ohlendorf D.H. Structure of toxic shock syndrome toxin 1. Biochemistry. 32(50):1993;13761-13766.
12. Schad E.M., Zaitseva I., Zaitsev V.N., Dohlsten M., Kalland T., Schlievert P.M.et al. Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO. J. 14(14):1995;3292-3301.
13. Swaminathan S., Furey W., Pletcher J., Sax M. Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature. 359(6398):1992;801-806.
14. Bonventre P.F., Heeg H., Cullen C., Lian C.J. Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun. 61(3):1993;793-799.
15. Bonventre P.F., Heeg H., Edwards C.K., Cullen C.M. A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity. Infect. Immun. 63(2):1995;509-515.
16. Drynda A., Konig B., Bonventre P.F., Konig W. Role of a carboxy-terminal site of toxic shock syndrome toxin 1 in eliciting immune responses of human peripheral blood mononuclear cells. Infect Immun. 63(3):1995;1095-1101.
17. Cullen C.M., Blanco L.R., Bonventre P.F., Choi E. A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation. Infect. Immun. 63(6):1995;2141-2146.
18. Earhart C.A., Mitchell D.T., Murray D.L., Pinheiro D.M., Matsumura M., Schlievert P.M.et al. Structures of five mutants of toxic shock syndrome toxin-1 with reduced biological activity. Biochemistry. 37(20):1998;7194-7202.
19. Papageorgiou A.C., Quinn C.P., Beer D., Brehm R.D., Tranter H.S., Bonventre P.F.et al. Crystal structure of a biologically inactive mutant of toxic shock syndrome toxin-1 at 2.5 A resolution. Protein Sci. 5(8):1996;1737-1741.
20. Hurley J.M., Shimonkevitz R., Hanagan A., Enney K., Boen E., Malmstrom S.et al. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1. J. Exp. Med. 181(6):1995;2229-2235.
21. Kum W.W., Wood J.A., Chow A.W. A mutation at glycine residue 31 of toxic shock syndrome toxin-1 defines a functional site critical for major histocompatibility complex class II binding and superantigenic activity. J. Infect. Dis. 174(6):1996;1261-1270.
22. Gampfer J., Thon V., Gulle H., Wolf H.M., Eibl M.M. Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome. Vaccine. 20(9/10):2002;1354-1364.
23. Stiles B.G., Krakauer T., Bonventre P.F. Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model. Infect. Immun. 63(4):1995;1229-1234.
24. Blanco L., Choi E.M., Connolly K., Thompson M.R., Bonventre P.F. Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody. Infect. Immun. 58(9):1990;3020-3028.
25. Kokan-Moore N P., Bergdoll M.S. Determination of biologically active region in toxic shock syndrome toxin 1. Rev. Infect. Dis. 11(1):1989;S125-S129.
26. Shimonkevitz R., Boen E., Malmstrom S., Brown E., Hurley J.M., Kotzin B.L.et al. Delineation by use of specific monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1. Infect Immun. 64(4):1996;1133-1139.
27. Blomster-Hautamaa D.A., Novick R.P., Schlievert P.M. Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromide-generated toxin fragments. J. Immunol. 137(11):1986;3572-3576.
28. Geysen H.M., Meloen R.H., Barteling S.J. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl. Acad. Sci. U.S.A. 81(13):1984;3998-4002.
29. Geysen H.M. Molecular technology: peptide epitope mapping and the pin technology. Southeast Asian J. Trop Med. Public Health. 21(4):1990;523-533.
30. Maeda H., Miyamoto M., Kokeguchi S., Kono T., Nishimura F., Takashiba S.et al. Epitope mapping of heat shock protein 60 (GroEL) from Porphyromonas gingivalis. FEMS Immunol. Med. Microbiol. 28(3):2000;219-224.
31. Matsushita K., Nisizawa T., Nagaoka S., Kawagoe M., Koga T. Identification of antigenic epitopes in a surface protein antigen of Streptococcus mutants in humans. Infect Immun. 62(9):1994;4034-4042.
32. Wood A.C., Chadwick J.S., Brehm R.S., Todd I., Arbuthnott J.P., Tranter H.S. Identification of antigenic sites on staphylococcal enterotoxin B and toxoid. FEMS Immunol. Med. Microbiol. 17(1):1997;1-10.
33. Warren J.R., Spero L., Metzger J.F. Antigenicity of formaldehyde-inactivated staphylococcal enterotoxin B. J. Immunol. 111(3):1973;885-892.
34. Lowell G.H., Kaminski R.W., Grate S., Hunt R.E., Charney C., Zimmer S.et al. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect Immun. 64(5):1996;1706-1713.
35. Kum W.W., Laupland K.B., Chow A.W. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J. Microbiol. 46(2):2000;171-179.
36. Pang L.T., Kum W.W., Chow A.W. Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody. Infect Immun. 68(6):2000;3261-3268.
37. Katz D., Lehrer S., Galan O., Lachmi B.E., Cohen S. Adjuvant effects of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and aluminium hydroxide on neutralizing antibody, antibody-isotype and delayed-type hypersensitivity responses to Semliki Forest virus in mice. FEMS Microbiol. Immunol. 3(6):1991;305-320.
38. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D.et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73(5):1999;4009-4018.
39. Kum W.W., Cameron S.B., Hung R.W., Kalyan S., Chow A.W. Temporal sequence and kinetics of proinflammatory and anti-inflammatory cytokine secretion induced by toxic shock syndrome toxin 1 in human peripheral blood mononuclear cells. Infect Immun. 69(12):2001;7544-7549.
40. Arad G., Levy R., Hillman D., Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat. Med. 6(4):2000;414-421. [in process citation].
41. Visvanathan K., Charles A., Bannan J., Pugach P., Kashfi K., Zabriskie J.B. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun. 69(2):2001;875-884.